About Hikal
Hikal is a company based in Mumbai (India) founded in 1988 by Jai Hiremath. The company has 3,600 employees as of March 31, 2024. Hikal offers products and services including Contract Development & Manufacturing, APIs and Intermediates, and Animal Health Products. Hikal operates in a competitive market with competitors including Laurus Labs, Symbiotec, Provepharm Life Solutions, Beijing Biostar Technologies and SeQuent, among others.
- Headquarter Mumbai, India
- Employees 3600 as on 31 Mar, 2024
- Founders Jai Hiremath
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Hikal Limited
-
Annual Revenue
$217.13 M (USD)4.15as on Mar 31, 2025
-
Net Profit
$10.63 M (USD)30.46as on Mar 31, 2025
-
EBITDA
$38.16 M (USD)22.31as on Mar 31, 2025
-
Latest Funding Round
$50 M (USD), Post-IPO
Nov 17, 2021
- Investors
-
Employee Count
3600
as on Mar 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Hikal
Hikal is a publicly listed company on the NSE with ticker symbol HIKAL in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Hikal
Hikal offers a comprehensive portfolio of products and services, including Contract Development & Manufacturing, APIs and Intermediates, and Animal Health Products.
Offers custom manufacturing for pharmaceutical and chemical products
Provides active pharmaceutical ingredients for various applications
Delivers intermediates and solutions for animal health sector
People of Hikal
Unlock access to complete
Unlock access to complete
Funding Insights of Hikal
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $50.0M
-
First Round
First Round
(01 Jun 2008)
- Investors Count 1
Investors in Hikal
Hikal has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include International Finance Corporation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
IFC is focused on private sector development in emerging markets.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Hikal
Financial Statements - Hikal
Hikal Comparisons
Competitors of Hikal
Hikal operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Symbiotec, Provepharm Life Solutions, Beijing Biostar Technologies and SeQuent, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pharmaceutical and biotechnology company
|
|
| domain | founded_year | HQ Location |
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
|
|
| domain | founded_year | HQ Location |
APIs and drug products are developed and valorized in pharmaceuticals.
|
|
| domain | founded_year | HQ Location |
APIs, intermediates, and biochemical reagents are developed and manufactured.
|
|
| domain | founded_year | HQ Location |
APIs are developed and manufactured for therapeutic areas.
|
|
| domain | founded_year | HQ Location |
Contract development, manufacturing, and analytical services for APIs are offered.
|
Frequently Asked Questions about Hikal
Hikal was founded in 1988 and raised its 1st funding round 20 years after it was founded.
Hikal is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
As of Mar 31, 2024, the latest employee count at Hikal is 3,600.
Annual revenue of Hikal is $217.13M as on Mar 31, 2025.
Hikal was founded in 1988 and is headquartered in Mumbai, India. Operations focus on the pharmaceutical and chemical sectors, where contract research, custom synthesis, and manufacturing of active pharmaceutical ingredients (APIs) and intermediates are conducted. Services extend to supplying ingredients for medicine production and providing research and development support for life sciences and biotechnology firms developing new products.
Hikal's top competitors include Laurus Labs, Symbiotec and Beijing Biostar Technologies.
Hikal offers Contract Development & Manufacturing, APIs and Intermediates, and Animal Health Products.
Yes, Hikal is publicly traded on NSE under the ticker symbol HIKAL.
Hikal has 1 investor. Key investors include International Finance Corporation.
The ticker symbol of Hikal is HIKAL on NSE.